Prevalence, characteristics and management of occult hepatitis B virus infection in patients with chronic lymphocytic leukemia: a single center experience

References

• Rossi D, Sala L, Minisini R, et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among treatment-naıve patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009;50: 604–611.
   PubMed Web of Science ®Google Scholar
• Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699–712.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Motokura T, Fujita A, et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer 1996;78:2210–2215.
   PubMed Web of Science ®Google Scholar
• Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001; 67:45–50.
   PubMed Web of Science ®Google Scholar
• Yagci M, Acar K, Sucak GT, et al. A prospective study on chemotherapy-induced hepatitis B virus reactivation in chronic HBs Ag carriers with hematologic malignancies and pre-emptive therapy with nucleoside analogues. Leuk Lymphoma 2006;47:1608–1612.
   PubMed Web of Science ®Google Scholar
• Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189–191.
   PubMedGoogle Scholar
• Niscola P, Del Principe MI, Maurillo L, et al. Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 2005;19:1840–1841.
   PubMed Web of Science ®Google Scholar
• Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005;74: 254–258.
   PubMed Web of Science ®Google Scholar
• Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Digest Liver Dis 2007;39:397–408.
   Web of Science ®Google Scholar
• Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652–657.
   PubMed Web of Science ®Google Scholar
• Penna A, Artini M, Cavalli A, et al. Long-lasting memory T-cell responses following self-limited acute hepatitis B. J Clin Invest 1996;98:1185–1194.
   PubMed Web of Science ®Google Scholar
• Huo TI, Wu JC, Lee PC, et al. Seroclearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 1998;28:231–236.
   PubMed Web of Science ®Google Scholar
• Marignani M, Gigante E, Begini P, et al. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol 2012;4:37–45.
   PubMedGoogle Scholar
• De Feo TM, Grossi P, Poli F, et al. Kidney transplantation from anti-HBc positive donors: results from a retrospective Italian study. Transplantation 2006;81:76–80.
   PubMed Web of Science ®Google Scholar
• Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008;2:152–162.
   PubMed Web of Science ®Google Scholar
• Picardi M, Pane F, Quintarelli C, et al. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003;88:1296–1303.
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Dieterich DT, Han SHB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6: 1315–1341; quiz 1286.
   PubMed Web of Science ®Google Scholar
• Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004;40:883–891.
   PubMed Web of Science ®Google Scholar
• Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis. J Hepatol 2006;44:283–290.
   PubMed Web of Science ®Google Scholar
• Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004;9:679–693.
   PubMed Web of Science ®Google Scholar
• Minuk GY, Lerner B, Gibson SB, et al. Hepatitis B and hepatitis C viral infections in patients with chronic lymphocytic leukemia. Can J Gastroenterol Hepatol 2014;28:131–134.
   PubMedGoogle Scholar
• Nakamura K, Yuh K, Sugyo S, et al. Apoptosis observed in peripheral T lymphocytes from patients with chronic hepatitis B. Gastroenterology 1996;111:156–164.
   PubMed Web of Science ®Google Scholar
• Ji W, Wang HF, Feng CQ. Activation-induced cell death in peripheral blood mononuclear cells (PBMCs) from patients with chronic hepatitis B may be related to abnormal production of interleukin 12 and 10. J Viral Hepat 2001;8:30–33.
   PubMed Web of Science ®Google Scholar
• Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010;25:864–871.
   PubMed Web of Science ®Google Scholar
• Barclay S, Pol S, Mutimer D, et al. The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting. J Clin Virol 2008;42: 104–115.
   PubMedGoogle Scholar
• Roche B, Samuel D. The difficulties of managing severe hepatitis B virus reactivation. Liver Int 2011;31(Suppl. 1):104–110.
   PubMed Web of Science ®Google Scholar
• Koo YX, Tan DS, Tan BH, et al. Risk of hepatitis B virus reactivation in patients who are hepatitis B surface antigen negative/antibody to hepatitis B core antigen positive and the role of routine antiviral prophylaxis. J Clin Oncol 2009;27:2570–2571; author reply 2571–2572.
   PubMed Web of Science ®Google Scholar
• Tur-Kaspa R, Burk RD, Shaul Y, et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986;83:1627–1631.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320–1328.
   PubMed Web of Science ®Google Scholar
• Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68–69.
   PubMed Web of Science ®Google Scholar
• Laurenti L, Vannata B, Innocenti I, et al. Chlorambucil plus rituximab as front-line therapy in elderly/unfit patients affected by B-cell chronic lymphocytic leukemia: results of a single-centre experience. Mediterr J Hematol Infect Dis 2013;5:e2013031.
   PubMedGoogle Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German CLL Study Group. J Clin Oncol 2012;30:3209–3216.
   PubMed Web of Science ®Google Scholar
• Günther G, Bartels S, Tessen HW, et al. Real-world efficacy and safety of bendamustine with or without rituximab in treatment-naïve patients with chronic lymphocytic leukemia: retrospective analysis of a German registry. Blood 2012;120(Suppl. 1):Abstract 2905.
   Google Scholar
• Leblond V, Laribi K, Ilhan O, et al. Rituximab in combination with bendamustine or chlorambucil for treating patients with chronic lymphocytic leukemia: interim results of a phase IIIb study (MaBLe). Blood 2012;120(Suppl. 1):Abstract 2744.
   Google Scholar
• Marzano A. Management of HBV infection during immunosuppressive treatment. Mediterr J Hematol Infect Dis 2009;1: e2009025.
   PubMedGoogle Scholar
• Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 2009; 113:3147–3153.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2009;50: 1–36.
   PubMed Web of Science ®Google Scholar
• Francisci D, Falcinelli F, Schiaroli E, et al. Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy. Infection 2010;38:58–61.
   PubMed Web of Science ®Google Scholar
• Sugauchi F, Tanaka Y, Kusumoto S, et al. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol 2011;83:412–418.
   PubMed Web of Science ®Google Scholar